Pursuant to Regulation 30 of Listing Regulations, Wockhardt has informed that it enclosed Press Release ‘Wockhardt Submits New Drug Application to U.S. FDA for Zidebactam-Cefepime (WCK 5222) for Treatment of Serious Gram-Negative Infections’. A copy of the same will also be uploaded on the Company’s website www.wockhardt.com.
The above information is a part of company’s filings submitted to BSE.